Annual report
4272.TEDINET S100QY0D
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 153
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥198.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥184.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥173.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥175.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥172.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥21.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥21.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥23.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥21.0bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥23.7bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥12.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥15.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥17.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥322.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥315.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥294.5bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥278.5bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥293.6bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥67.8bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥69.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥255.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥246.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥228.3bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥210.0bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥229.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥48.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥38.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥53.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥47.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥52.7bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥20.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥24.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥27.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥26.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥15.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥8.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥13.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥89.36 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.62 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.25 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.77 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥89.33 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥101.65 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.61 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥74.23 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥85.75 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,532.35 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,459.06 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,332.06 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,225.71 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,247.75 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 78.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.2% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.6% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.0% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,782 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,703 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 5,664 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,847 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,814 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥128.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥124.0bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥115.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥106.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥103.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥10.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥11.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥17.2bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥16.1bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥13.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥15.5bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥16.5bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥12.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥12.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥22.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥237.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥236.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥230.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥215.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥208.0bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥52.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥51.6bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥185.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥184.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥180.4bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥160.8bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥161.7bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥16.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥75.33 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.63 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.38 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.01 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.19 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥45 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,117.38 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,098.36 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,056.38 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥941.59 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥934.13 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 78.0% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 170,503,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 170,503,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,503,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,503,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 182,503,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,391 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 2,398 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 2,401 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 2,069 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 2,079 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 102
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥627m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥746m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 122 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥10.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥110m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥19.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥368m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥472m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥274m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥274m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥50.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥7.6bn |
| Functional Chemicalsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥5.9bn |
| Functional Chemicalsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5.0bn |
| Functional Chemicalsreportable segment | employees | at 2023-03-31 | 2130 pure |
| Functional Chemicalsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥81.9bn |
| Functional Chemicalsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥81.7bn |
| Functional Chemicalsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥163m |
| Functional Chemicalsreportable segment | segment assets | at 2023-03-31 | ¥103.0bn |
| Functional Chemicalsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥10.6bn |
| Pharmaceuticalsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Pharmaceuticalsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.9bn |
| Pharmaceuticalsreportable segment | employees | at 2023-03-31 | 821 pure |
| Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥51.7bn |
| Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥51.7bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Pharmaceuticalsreportable segment | segment assets | at 2023-03-31 | ¥64.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥8.7bn |
| Safety Systemsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥3.5bn |
| Safety Systemsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5.6bn |
| Safety Systemsreportable segment | employees | at 2023-03-31 | 2498 pure |
| Safety Systemsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥54.2bn |
| Safety Systemsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥54.2bn |
| Safety Systemsreportable segment | segment assets | at 2023-03-31 | ¥85.7bn |
| Safety Systemsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥11.5bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥12.5bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥187.8bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥187.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥163m |
| —segment total | segment assets | at 2023-03-31 | ¥252.8bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥27.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥13.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥198.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥198.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥274m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥272.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥29.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥851m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥701m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥9.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥105m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥19.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥1.8bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥356m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥527m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥249m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥249m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥55.7bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥7.2bn |
| Functional Chemicalsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.6bn |
| Functional Chemicalsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥5.0bn |
| Functional Chemicalsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥77.3bn |
| Functional Chemicalsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥77.2bn |
| Functional Chemicalsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥143m |
| Functional Chemicalsreportable segment | segment assets | at 2022-03-31 | ¥104.7bn |
| Functional Chemicalsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥11.5bn |
| Pharmaceuticalsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.8bn |
| Pharmaceuticalsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥52.1bn |
| Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥52.1bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥0 |
| Pharmaceuticalsreportable segment | segment assets | at 2022-03-31 | ¥58.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥8.6bn |
| Safety Systemsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Safety Systemsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| Safety Systemsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥46.1bn |
| Safety Systemsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥46.1bn |
| Safety Systemsreportable segment | segment assets | at 2022-03-31 | ¥77.0bn |
| Safety Systemsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥6.3bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥7.9bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥12.3bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥175.5bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥175.3bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥144m |
| —segment total | segment assets | at 2022-03-31 | ¥239.8bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥26.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥185.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥184.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥249m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥259.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥28.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 122 pure |
| Functional Chemicalsreportable segment | employees | at 2023-03-31 | 965 pure |
| Pharmaceuticalsreportable segment | employees | at 2023-03-31 | 765 pure |
| Safety Systemsreportable segment | employees | at 2023-03-31 | 330 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,076
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity in losses of affiliates noe | Prior1YearDuration | － | JPY |
| Equity in losses of affiliates noe | CurrentYearDuration | 503000000 | JPY |
| Idle real estate related expenses noe | Prior1YearDuration | 48000000 | JPY |
| Idle real estate related expenses noe | CurrentYearDuration | 44000000 | JPY |
| Other noe | Prior1YearDuration | 260000000 | JPY |
| Other noe | CurrentYearDuration | 345000000 | JPY |
| Non operating expenses | Prior1YearDuration | 391000000 | JPY |
| Non operating expenses | CurrentYearDuration | 996000000 | JPY |
| Ordinary income | Prior1YearDuration | 23154000000 | JPY |
| Ordinary income | CurrentYearDuration | 23025000000 | JPY |
| Gain on change in equity ei | Prior1YearDuration | － | JPY |
| Gain on change in equity ei | CurrentYearDuration | 123000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YearDuration | 1394000000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYearDuration | 488000000 | JPY |
| Gain on sales of investment securities ei | Prior1YearDuration | 390000000 | JPY |
| Gain on sales of investment securities ei | CurrentYearDuration | 766000000 | JPY |
| Extraordinary income | Prior1YearDuration | 1785000000 | JPY |
| Extraordinary income | CurrentYearDuration | 1377000000 | JPY |
| Impairment loss el | Prior1YearDuration | 91000000 | JPY |
| Impairment loss el | CurrentYearDuration | 2127000000 | JPY |
| Loss on disposal of noncurrent assets el | Prior1YearDuration | 618000000 | JPY |
| Loss on disposal of noncurrent assets el | CurrentYearDuration | 698000000 | JPY |
| Loss on valuation of investment securities el | Prior1YearDuration | 528000000 | JPY |
| Loss on valuation of investment securities el | CurrentYearDuration | 605000000 | JPY |
| Extraordinary loss | Prior1YearDuration | 1238000000 | JPY |
| Extraordinary loss | CurrentYearDuration | 3431000000 | JPY |
| Income before income taxes | Prior1YearDuration | 23700000000 | JPY |
| Income before income taxes | CurrentYearDuration | 20972000000 | JPY |
| Income taxes current | Prior1YearDuration | 5728000000 | JPY |
| Income taxes current | CurrentYearDuration | 5954000000 | JPY |
| Income taxes deferred | Prior1YearDuration | 727000000 | JPY |
| Income taxes deferred | CurrentYearDuration | -24000000 | JPY |
| Income taxes | Prior1YearDuration | 6455000000 | JPY |
| Income taxes | CurrentYearDuration | 5929000000 | JPY |
| Profit loss | Prior1YearDuration | 17244000000 | JPY |
| Profit loss | CurrentYearDuration | 15042000000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YearDuration | 63000000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYearDuration | 57000000 | JPY |
| Profit loss attributable to owners of parent | Prior1YearDuration | 17181000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYearDuration | 14984000000 | JPY |
| Profit loss | Prior1YearDuration | 17244000000 | JPY |
| Profit loss | CurrentYearDuration | 15042000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YearDuration | -274000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYearDuration | -1795000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YearDuration | 9054000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYearDuration | 6726000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YearDuration | 106000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYearDuration | -927000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | Prior1YearDuration | -7000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | CurrentYearDuration | 4000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |